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Evaluation of Oncology Nurses’ Knowledge, Practice Behaviors, and Confidence
Specific to Chemotherapy Induced Peripheral Neuropathy

R. Denise McAllister
Abstract
Chemotherapy induced peripheral neuropathy (CIPN) remains one of the most
serious and challenging symptoms oncology nurses encounter in caring for patients
receiving neurotoxic chemotherapy. CIPN is under-addressed, under-reported, and
symptoms are minimized by healthcare providers, which adversely affect patient quality
of life, physical function, and emotional well-being. There is an absence of research
examining nurses’ knowledge and practice behaviors related to CIPN. The purpose of
this study was to explore oncology nurses knowledge, practice behaviors, confidence, and
the relationship between education, experience, and knowledge specific to CIPN.
Data was collected at Oncology Nursing Society (ONS) Chapter meetings
throughout central and south Florida. The sample consisted of 70 oncology nurses who
provide direct care to patients with cancer. Participants completed the CIPN: Assessment
of Oncology Nurses’ Knowledge and Practice–Revised questionnaire. Demographic data
revealed the overall years of nursing experience mean to be 24.7 (SD=12.2), mean years
of oncology experience to be 13.5 (SD=7.5), and mean age to be 50.3 years (SD=9.5).
The participants varied in highest attained level of education with the majority having
Bachelor of Science degrees (40.0%).
iv

The results of this study revealed adequate nursing knowledge pertaining to CIPN
13.0 (SD=1.9) (81%). Fifty-percent of nurses reported always or frequently screening for
CIPN. The majority of participants reported always or frequently; evaluating fine motor
skills (68.6%), documenting findings (64.3%), assessing risk factors (55.7%), assessing
motor function (52.9%), performing assessment prior to each neurotoxic chemotherapy
infusion (58.6%), eliciting patient symptoms (65.7%), teaching strategies for adaptation
(57.1%), and teaching safety precautions (74.3%). Nurses less frequently reported always
or frequently assessing deep tendon reflexes (17.2%) and assessing muscle strength
(35.7%). The majority reported confidence in sharp vs. dull sensation testing (62.8%),
and manual muscle strength testing (52.9%), while the majority lacked confidence
performing deep tendon reflex testing (71.5%), tuning fork vibration sensation testing
(72.8%), and Romberg testing (72.8%). There was a significant relationship between
highest educational level achieved and knowledge of CIPN (r=.252, p=.037).
This is one of two studies documenting oncology nurses’ knowledge, practice
behaviors, and confidence specific to CIPN. Findings lay the foundation in documenting
the need for providing oncology nurses with continued education, and the need to teach
oncology nurses the skills necessary to confidently assess for CIPN and interpret the
findings.

v

Chapter I: Introduction
The American Cancer Society (ACS) estimates 1,500,000 people are diagnosed
with cancer annually with an estimated 11.1 million Americans living after a cancer
diagnosis (ACS, 2009). Chemotherapy is an integral component of the cancer treatment
paradigm that promotes cure, disease control, or palliation of symptoms. Chemotherapyinduced peripheral neuropathy (CIPN) is a serious clinical problem that affects those
receiving: platinum based compounds; taxanes; plant alkaloids; biologics;
antiangiogenesis agents; and proteasome inhibitors used for treatment of a variety of solid
and hematologic malignancies (Visovsky, Collins, Abbott, Aschenbrenner, & Hart, 2007;
Wilkes, 2007). Despite advances in therapies and side effect management, CIPN remains
one of the most challenging symptoms oncology nurses encounter in caring for patients
receiving neurotoxic chemotherapy (Wilkes, 2007).
Sensory signs and symptoms may include tingling, numbness, and burning in the
hands and feet. Usually the symptoms are bilateral and are worse in the lower extremities.
Symptoms may also include pain, and loss of vibratory, position, and temperature sense,
touch, deep tendon reflexes, and two-point discrimination (Armstrong, Almadrones, &
Gilbert, 2005). CIPN causes a disruption in work responsibilities and leisure activities
with functional deficits based on location of paresthesias involving fingers, hands, arms,
toes, feet, and legs (Bakitas, 2007). Functional effects of CIPN include but are not limited
to; mobility and safety issues, weakness of extremities, inability to sense temperature
changes, difficulty performing tasks that require hand and foot manipulation, and pain in
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affected extremities (Bakitas, 2007; Tofthagen, 2010). Risk factors for CIPN include
exposure to neurotoxic chemotherapy, concurrent use of neurotoxic medications,
previous radiation to spinal fields causing pre-existing neuropathy, malignancies
associated with pre-existing neuropathy such as multiple myeloma, co-morbid conditions
such as diabetes mellitus, hypothyroidism, vitamin B deficiencies, human
immunodeficiency virus, renal insufficiency, and alcoholism (Armstrong, et al., 2005;
Wickham, 2006).
CIPN is under-addressed, under-reported, and minimized by oncology healthcare
providers causing patients to suffer the ill effects of chemotherapy induced peripheral
neuropathy and lack of management (Smith, Beck, & Cohen, 2008). The experience of
CIPN negatively influences patient’s daily lives, adversely affecting quality of life (QOL)
and physical function of patients with cancer who receive neurotoxic chemotherapy
agents (Bakitas, 2007; Tofthagen, 2010). In addition to compromising patients’ QOL,
treatment dose reductions, treatment discontinuation, or treatment postponement can
occur due to the dose-limiting toxicity of CIPN (Kuroi et al., 2008; Visovsky, et al.,
2007).
Problem Statement
There is an absence of research examining oncology nurses’ knowledge of
pathophysiology of the peripheral nervous system, neurotoxic effects of chemotherapy,
interventions used to manage CIPN, and the impact of CIPN to those receiving
neurotoxic agents. Research is needed to examine nurse’s knowledge of this phenomenon
because knowledge is pre-requisite to practice (Curley, 1998). Oncology nurse’s
knowledge of CIPN needs to be assessed and any identified deficits need to be rectified
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for the preservation of safety and improved QOL of oncology patients. The purpose of
this study was to explore oncology nurses’ knowledge, practice behaviors, and
confidence in assessing for CIPN.
Research Questions
The aim of this study was to answer the following research questions:
1. What is the level of knowledge among oncology nurses regarding CIPN?
2. What are oncology nurses’ self-reported practice behaviors in assessing for CIPN?
3. How confident are oncology nurses in assessing CIPN in their patients?
4. What is the relationship between oncology nurses experience, level of education, and
knowledge specific to CIPN?
Definitions of Terms
For the purpose of this study, the following terms are defined:
Peripheral nervous system: the portion of the nervous system that is outside the brain and
spinal cord, that transmits information between the central nervous system (e.g. the brain
and spinal cord) and the rest of the body (Sweeney, 2002).
Chemotherapy induced peripheral neuropathy: neuromuscular systems due to damage to
the peripheral nervous system, induced by neurotoxic chemotherapeutic agents
(Visovsky, et al., 2007).
Function: ability to perform activities related to personal care and role responsibility
(Barsevick, Much, & Sweeney, 2000).
Quality of life: patients’ self-assessment of and satisfaction with their current level of
functioning compared to what is perceived to be possible or ideal (Cella, & Tulsky,
1990).

3

Significance to Nursing
Symptom management and improving QOL are the primary focus of oncology
nursing. CIPN is an unpleasant symptom that can potentially adversely affect the QOL,
function, and safety of patients with cancer. Nurses can advocate on behalf of patients by
understanding the distressing influence and long-term sequella CIPN can have on daily
living. It is estimated ten to one-hundred percent of patients with cancer will develop
CIPN depending on drugs, dosages, existing co-morbid conditions, and measurement tool
utilized by the healthcare team (Bakitas, 2007). Nurses being in the forefront of oncology
care are in the best position to identify neurotoxic agents, educate patients on early
symptoms, assess for symptoms, and anticipate the care the patient will require with the
intent to minimize or alleviate the burden of CIPN. Nurses have a great opportunity to
evaluate their own knowledge of CIPN regarding assessment and intervention strategies
relevant to clinical practice for the preservation of safety and improved QOL of the
oncology patient. This study may shed light on oncology nurses’ level of knowledge,
practice behaviors, confidence in neurological assessment pertaining to CIPN, and the
relationship between knowledge of CIPN, and level of education, and nursing experience.
The results of this study will be applied to the creation of a larger intervention study
aimed at the management of CIPN. In addition, data generated from this study will help
direct educational programs for oncology nurses.
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Chapter II: Review of the Literature
This chapter outlines the review of literature. The theoretical framework is
presented first, followed by pathophysiology, impact of CIPN on function and QOL,
measurement tools, prevention and treatment strategies, and a summarization of the
literature.
Theoretical Framework
The Synergy Model for Patient Care developed by the American Association for
Critical Care Nursing provides the conceptual framework for this research. The premise
of the Synergy Model for Patient Care, is when patient characteristics and nurses
competencies match, optimal patient outcomes are achieved (Curley, 1998).The model
identifies eight common characteristics displayed by patients when confronted with a
health issue. These include resiliency, vulnerability, stability, complexity, resource
availability, participating in care, participating in decision-making, and predictability.
These characteristics aid the nurse in anticipating the needs of patients and providing
optimal care based on the patient’s unique needs. The identified nursing characteristics
include clinical judgment, advocacy-moral agency, caring practices, collaboration,
systems thinking, response to dignity, clinical inquiry, and facilitator of learning
(Arashin, 2010; Curley, 1998). The Synergy Model can be incorporated to guide clinical
practice with CIPN as the primary focus. CIPN can place patients in a vulnerable state
with possible compromise to treatment outcomes and can induce physiological or
psychological stress. Nurses can identify a predictive path based on disease, risk factors,
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selection of neurotoxic agents, and noting how patients are responding to neurotoxic
chemotherapy. Oncology nurses can apply their clinical expertise, provide compassionate
care, advocate on behalf of patients, and collaborate with interdisciplinary team members
when approaching the care of patients with CIPN to minimize or alleviate the burden of
CIPN.
Pathophysiology of CIPN
The nervous system is comprised of the central nervous system (CNS) and
peripheral nervous system (PNS). The PNS consist of sensory, motor, and autonomic
nerves. The sensory nerve fibers transmit impulses from the periphery to the CNS. The
motor nerve fibers transmit impulses from the CNS to the muscles or organs. The large
myelinated sensory nerves control vibration and position sense and unmyelinated small
fiber sensory nerves control pain, perception of touch, and temperature. Motor nerves
control voluntary movement, coordination, and maintain muscle tone. The autonomic
peripheral nerves control blood pressure, intestinal motility, and involuntary muscles
(Armstrong, et al., 2005; Wilkes, 2007).
The underlying pathophysiology rationale for developing CIPN has not been fully
described, because of incomplete understanding. The pathogenesis may vary depending
on the neurotoxic agent administered. Neurotoxic chemotherapeutic agents are thought to
damage sensory axons, leading to degeneration and dying back of axons and myelin
sheaths. Axons can regenerate, however, damage to cell bodies is often not reversible
(Wickham, 2006).
Patients commonly speak of severe symptoms of CIPN causing interference with
physical function including the inability to button clothing, write, drive, or walk (Bakitas,

6

2007; Tofthagen, 2010). Sensory signs and symptoms include numbness, tingling,
burning, pain, ataxia, loss of deep tendon reflexes, and reduced sense of touch, vibration,
and proprioception. Motor symptoms include weakness, gait disturbances, balance
disturbances, and difficulty with fine motor skills. Autonomic symptoms include
constipation, urinary retention, sexual dysfunction, and altered blood pressure (Bakitas,
2007; Visovsky, et al., 2007; Wilkes, 2007). These CIPN symptoms may be acute, mild
or severe, transient, or prolonged (Postma, & Heimans, 2000).
Symptoms of CIPN are related to the affected nerve fibers. Sensory changes are
usually noted first in the toes and feet, the fingers and hands second, followed by a
proximal progression to the ankles and wrist in a stocking glove-manner (Wolf, Barton,
Kottschade, Gothey, & Loprinzi, 2008). The distribution of symptoms is bilateral and
symmetrical. Symptoms of CIPN can become progressively worse after discontinuing the
neurotoxic agent. This phenomenon is known as coasting and occurs as result of
receiving a cumulative amount of drug. The onset is usually a gradual progression;
however, rapid onset can occur after receiving a neurotoxic agent (Wilkes, 2007).
Patients with pre-existing conditions, such as diabetes mellitus, alcohol related peripheral
neuropathy, ischemic disease, vitamin deficiencies, renal insufficiency, prior exposure, or
concurrent use of neurotoxic agents could be at increased risk for CIPN (Armstrong, et
al., 2005; Wilkes, 2007).
Peripheral neuropathy may be reversible with dose modification or
discontinuation, and in some cases; the damage is irreversible. The incidence and type of
CIPN is dependant on the causative drug (Table 1) (Wilkes, 2007).
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Table 1
CIPN: Causative Agent, Incidence, and Type
Agent
Incidence
Carboplatin
Cisplatin

13%-42%
57%-92%

Oxaliplatin
13%-92%
Paclitaxel
59%-78%
Docetaxol
20%-58%
Vincristine
57%
Vinorelbine
7%-31%
Bortezomib
35%
Thalidomide
22%-54%
Note. Adopted from Wilkes (2007).

Type

Sensory progressing to mixed sensori-motor
Sensory progressing to mixed sensorimotor, autonomic
Sensory, autonomic
Mixed sensori-motor
Sensori-motor
Mixed sensori-motor, autonomic
Motor and autonomic
Sensory, mixed sensori-motor
Sensori-motor

Impact on Function and QOL
Symptoms of CIPN, other than numbness and tingling in the hands and feet have
gained little attention in the literature. Bakitas (2007) purposely recruited 28 participants
from a rural National Cancer Institute designated comprehensive cancer center to this
qualitative study to better understand the impact of CIPN on daily living and function.
The eligibility criteria included patients identified as having numbness, tingling, burning,
shock-like, or painful sensations present bilaterally in feet or hands that was not present
prior to initiation of chemotherapy, and found to be related to the initiation of
chemotherapy. Demographics of participants included; mean age 59 years +/- 9.6 with an
age range of 46-81 years, 71% female, median time since diagnosis was 34 months with
range of 3-198 months, 50% had breast cancer, 21% had hematologic malignancies, 11%
had ovarian cancer, 11% had colon cancer and 7% other malignancies. Primary data
collection occurred through individual 25-90 minute interviews, which were audiotaped
and transcribed into more than 700 pages of text. Data was analyzed using content
analysis and constant comparison.
8

In this, qualitative study by Bakitas (2007), CIPN was best described as a constant
drone that was distracting and unpleasant like that of background noise. Four themes that
further defined the CIPN experience were becoming aware, learning new lyrics,
functional, emotional, and social cacophony, and learning to live with CIPN. The
awareness involved noticing symptoms, monitoring for changes, evaluating function,
ignoring intense symptoms, and notifying the healthcare team of symptoms. Learning
new lyrics symbolizes the difficulty patients had communicating the sensation of CIPN to
the healthcare team so the symptoms could be understood. Role cacophony describes the
interruption in activities of daily living, leisure, work, and role within the family. Some
felt isolated when they could not participate in social activities. CIPN was also
considered emotionally distressing. Learning to live with CIPN represents the trade-off
for the benefit of treatment although the potential for irreversible nerve damage and
permanent disability was of concern. Half of patients reported they had no recall of
receiving education on CIPN. Patients reported healthcare providers assessed for CIPN,
although rarely asked about the impact on daily living. Some received a change in
chemotherapy or medications to control symptoms, while others ignored the symptoms
and adjusted planned activities because of symptoms. The findings of this study
contribute to the clarity of how those affected by CIPN live each day (Bakitas, 2007).
Tofthagen (2010) describes the effects of CIPN and neuropathic pain in the lives
of 14 patients with cancer. The sample consisted of 8 men and 6 women, ranging in age
from 42-84 years. The cancer diagnoses of the participants included breast (28%), lung
(28%), colorectal (22%), multiple myeloma (14%), and cholangeocarcinoma (7%).
Participants received neurotoxic chemotherapy regimens containing paclitaxel (28%),
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oxaliplatin (28%), docetaxel (22%), thalidomide (14%), or vinorebine (7%) and must
have received these agents within three years of data collection. Semistructured
interviews were conducted, recorded, and transcribed. The interviews ranged 10-45
minutes in length, with participants being asked six questions related to CIPN symptoms;
words to describe these symptoms; affect on daily life; interference with ability to
function; what is most troubling about these symptoms; and participants were given
opportunity to share any additional information about these symptoms.
Participants reported a combination of sensory and motor symptoms associated
with and without pain symptoms. The non-painful symptoms reported include numbness
of fingers and toes (100%), loss of balance (57%), muscle weakness (57%), tingling
(50%), generalized weakness (43%), lack of coordination (14%), short-term memory loss
(14), trouble concentrating (14%), and loss of depth perception (7%). Almost 50% of
patients reported near or actual injuries because of non-painful symptoms with 43% of
participants reported being ambulatory prior to treatment who now require assistive
devices to ambulate. Painful symptoms were reported including cold sensitivity (50%),
pain (71%), burning (43%), muscle aches (36%), pins and needles (29%), soreness
(22%), tremors (22%), jaw pain (14%), joint pain (14%), sharp pain (14%), shooting pain
(14%), electric-like pain (7%), pressure (7%), stabbing pain (7%), and trampling pain
(7%). Although patients had difficulty expressing or describing the painful sensation, the
pain was located primarily in the upper and lower extremities. Neuropathic symptoms
were described as interfering with usual activities such as activities of daily living (57%),
walking (50%), picking up items (43%), driving (36%), hobbies (36%), relationships

10

(29%), household chores (22%), manual dexterity (22%), work (22%), writing (14%),
exercise (7%), sexual activity (7%), and sleep (7%).
The researcher reports patients had difficulty articulating symptoms of CIPN,
which is consistent with the literature. The participants have been coping with
neuropathic symptoms for up to three years and expressed their QOL had been adversely
affected. The interference with ability to perform activities is a source of great emotional
distress. This study supports the negative influences CIPN has on QOL, functional
capacity, and emotion well being.
Measurement Tools
CIPN was once considered a minor problem that would resolve over time and
seldom led to profound limitations (Smith, et al., 2008). This ideology has posed an
important challenge to neuropathy measurement in the oncology setting. Commonly used
grading scales, such as the National Cancer Institute Common Toxicity Criteria for
Adverse Events (NCI-CTCAE) (National Cancer Institute, 2003), Eastern Cooperative
Oncology Group (ECOG) (Oken, Creech, Tormey, Horton, Davis, McFadden, et al.
1982),World Health Organization (WHO) (Miller, Hoogstraten, Staquet, & Winkler,
1981), and Ajani (Ajani, Welch, Raber, Fields, & Krakoff, 1990) have different
definitions of grade and do not define terms (Wilkes, 2007). This allows for subjective
interpretation on behalf of healthcare providers leading to ambiguities when deciding
treatment modifications based on current grading tools.
An important study evaluating the inter-examiner and inter-test reliability
between widely used grading scales was conducted by Postma, Heimans, Muller,
Ossenkoppele, Vermorken, & Aaronson, (1998). Two neurologists independently rated
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the severity of CIPN in 37 patients with 148 observations according to WHO, ECOG,
Ajani, and NCI-CTCAE criteria. The majority of participants were female with ovarian
cancer who had previously received paclitaxel and cisplatin. The percentage of
interobserver agreement on all grades of CIPN ranged from 46% to 84% (NCI-CTCAE
46%, Ajani 57%, ECOG 76%, and WHO 84%). A comparison of the different grading
scales showed the interobserver agreement utilizing grades 0 to 4 was the lowest using
the NCI-CTCAE grading scale at 45.9% while the agreement on severe (grade 3)
neuropathy using the NCI-CTCAE was 42% with 58% disagreement. The interobserver
agreement between the ECOG grade 3 CIPN was 40% and 0% for the WHO and Ajani
criteria. This study demonstrates clinicians interpret the evaluation criteria and grading
for CIPN differently. The authors stated the differences occur when accounting for the
interpretation of patient symptoms related to interference with function. These widely
accepted grading tools do not incorporate patient’s subjective experiences of daily living
and functional impairment in the scale parameters. These tools are useful for identifying
patients who are need of neurological examination, however do not reflect the extent and
severity of CIPN (Postma, et al., 1998).
In an effort to quantify the symptoms and severity of CIPN, the Patient
Neurotoxicity Questionnaire (PNQ) was developed by BioNumerik Pharmaceuticals with
input from the Food and Drug Administration (FDA). It is a simple self-administered
patient based questionnaire designed to delineate between interference and no
interference in activities of daily living (ADL) resulting from CIPN (Hausheer, Schilsky,
Bain, Berghorn, & Liberman, 2006). Shimozuma, Ohashi, Takechi, Morita, Ohsmi,
Sunada, et al. (2004) evaluated the validity of this patient-based instrument with the
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clinician-based instrument NCI-CTCAE and the Functional Assessment of Cancer
Therapy-Taxane including neurotoxicity component (FACT/GOG-Ntx). The PNQ was
utilized in a Phase III randomized trial comparing four treatment arms of different
adjuvant taxane containing regimens in breast cancer patients in evaluating symptoms of
neurotoxicity. CIPN symptoms were prospectively assessed in 300 patients at day thirtyeight following surgery and at baseline, cycle three, cycle five, and cycle seven of
starting adjuvant therapy. The mean age was 51.7 years +/- 8.9, 55% had 1-3 positive
nodes, 26.7% had.4-9 positive nodes, 18.3% had 10 or greater positive nodes. This study
demonstrated that in a defined population of patients receiving neurotoxic chemotherapy,
the PNQ is a reliable, sensitive, responsive instrument in the diagnosis and grading of
CIPN with greater sensitivity than the FACT-Ntx and NCI-CTCAE. A lower incidence of
severe forms of CIPN was reported by physicians based on the NCI-CTCAE as compared
to the PNQ, thus demonstrating CIPN is under-reported by physicians. Kuroi et al. (2008)
in a qualitative analysis evaluated the physicians’ perspectives regarding the utility and
diagnostic value of the PNQ to assess CIPN. A questionnaire was sent to sixty-one
physicians who participated in a Phase III randomized trial of adjuvant chemotherapy in
breast cancer that used the PNQ to assess CIPN. Seventy-seven percent responded. The
study concluded that neurosensory disturbances interfering with ADL are justification for
treatment modifications. Based on the PNQ, moderate symptoms are justification for
postponing treatment and severe symptoms should result in treatment discontinuation.
Eighty-four percent reported the PNQ was helpful in the diagnosis and assessment of
patients at risk for CIPN. The FDA has supported the use of the PNQ as a primary end
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point in assessing the incidence and severity of CIPN in phase II and phase III trials in
the United States (Hausheer, et al., 2006).
Oncology nurses’ assessment is critical to early identification. Assessment of
neurological function on a routine basis, monitoring those at risk is crucial to successful
intervention. Smith et al (2008) reports the Total Neuropathy Score (TNS) developed for
neurologist has been described as the most comprehensive tool available and should be
considered for use by oncology nurses in evaluating for CIPN. This scoring system (0-32
points) combines subjective sensory symptoms, subjective report of symptoms and
amount of difficulty with daily activities, deep tendon reflex testing, manual muscle
testing of muscles for the wrist and ankle, pin sensibility, quantitative vibration
thresholds, and nerve conduction studies. This tool assesses neuropathy signs and
symptoms and incorporates nerve conduction study results, but does not adequately
assess painful neuropathy. The systematic review of seven studies describes the
psychometric properties, clinical significance, and the utility of the TNS in assessing
CIPN. This data synthesis concludes, this tool is too labor intensive for clinical practice,
and inadequately assesses the pain component of neuropathy. This author also states, with
basic physical assessment training and practice, nurses can become skilled at neuropathy
assessment.
Binner (2010) developed the Chemotherapy-Induced Peripheral Neuropathy:
Assessment of Oncology Nurses’ Knowledge and Practice, a questionnaire to determine
the knowledge oncology nurses have specific to CIPN and to evaluate practice behaviors
and CIPN assessment skills. The questionnaire contains 16 knowledge items, 16 practice
items, and 9 demographic items related to skills, instructions, and perceptions. The test
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was administered to 39 oncology nurses in 2 outpatient infusion clinics. Test results were
evaluated for reliability.
This study indicated oncology nurses have adequate knowledge of CIPN with a
mean knowledge score 12.6 (79%), out of a possible 16. All respondents indicated
assessment of CIPN is essential to their role, 75% rated their CIPN assessment skills as
fair to poor. Only 25% rated their assessment skills as good, and none rated their
assessment skills as excellent. General physical assessment practices did not routinely
include neurological physical assessment, 56.4% always or frequently perform baseline
screening, 76.9 % always or frequently assess fine motor skills, 74.3% always or
frequently document findings, 51.3% always or frequently assess risk factors, 76.9%
always or frequently perform CIPN assessment prior to each infusion of a neurotoxic
agent, 89.7% elicit symptoms of CIPN, 79.5% teach safety precautions. Oncology nurses
reported never or occasionally performing deep tendon reflex testing (97.4%), muscle
strength testing (77%), never or occasionally performing gross motor function testing
(69.2%). The content validity index of this instrument was determined to be 0.95, and the
internal consistency reliability was shown to be high, with a Cronbach’s alpha score of
0.84.
Prevention and Treatment Strategies
Visovsky and colleagues (2007) constructed an evidenced based review of
interventions aimed at the prevention and treatment of CIPN. The Oncology Nursing
Society published this systematic review as a guide for oncology nursing practice. This
analysis highlights a review of pharmacologic intervention studies utilizing amifostine,
vitamin E, calcium and magnesium, nortriptyline, carbamazpine, acetyl-L-carnine,
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glutamine, glutathione, alpha lipoic acid, and human leukemia factor for the prevention
or reduction in CIPN. There is not enough evidence that meets the scientific rigor
required to suggest any pharmacologic interventions for clinical practice. Nonpharmacologic interventions such as acupuncture, assistive devices, pulsed infrared light
therapy, transcutaneous nerve stimulation, capsaicin ointment, and spinal cord
stimulation do not have established effectiveness in the prevention or treatment of CIPN.
The studies evaluating the above non-pharmacologic interventions have limited or
complete absence of data in the oncology population.
Summary
Chemotherapy induced peripheral neuropathy (CIPN) is an untoward side effect
that can potentially adversely affect the quality of life of patients with cancer who receive
neurotoxic chemotherapeutic agents. Oncology nurses face many challenges in providing
comprehensive care to patients receiving cancer therapies that can result in CIPN. The
literature supports a lack of a standard comprehensive, reliable, valid measurement tool
that captures early symptoms of CIPN. Kuroi et al. (2008) reports the current tools do not
consider the patients’ verbal reporting of symptoms of PN. The inability for patients to
adequately articulate the symptoms of PN can be problematic for oncology practitioners
in understanding the symptoms and the impact long term. The National Cancer Institute
Common Toxicity Criteria for Adverse Events (CTCAE), World Health Organization
(WHO), and Eastern Cooperative Oncology Group (ECOG) have different definitions of
grade and do not define terms, which allows for subjective interpretation leading to
ambiguities when deciding upon treatment modifications.
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Visovsky et al. (2007) through the ONS Putting Evidence Into Practice (PEP)
initiative provides a comprehensive review of the literature with no identified large,
randomized, double-blind clinical trials showing pharmacologic and non-pharmacologic
efficacy in the prevention and treatment of CIPN.
Smith and colleagues (2008) reviewed the literature evaluating the usefulness of
the Total Neuropathy Score (TNS) as an instrument designed to quantify CIPN that
nurses may incorporate into clinical practice. It was determined this comprehensive tool
assessing both subjective and objective aspects of peripheral nerve function lacked
validity, adequate neuropathic pain assessment, and would require nurses to have basic
knowledge of physical neurological assessment. Binner (2010) developed the first tool to
explore oncology nurses’ knowledge and practice behaviors specific to CIPN. This study
concluded oncology nurses have adequate knowledge related to CIPN, CIPN assessment
skills were rated as fair to poor by 75%, and assessment practices to not routinely include
neurological physical assessment. This instrument was found to be valid and reliable with
a Cronbach’s alpha score =0.84.This study is the only one to evaluate oncology nurses
knowledge and practice behaviors.
Bakitas (2007) evaluated 28 study participants in an attempt to clarify the CIPN
symptom experience and the influence on everyday living. The metaphor of background
noise was used to describe the constant drone of living with CIPN. Tofthagen (2010)
purposely evaluated 14 oncology patients in a descriptive analysis examining the effects
of CIPN and neuropathic pain. The participants described sensory and motor symptoms,
with and without pain. The negative effects of CIPN on the physical and emotional
wellbeing of patients with cancer are clearly described.
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Chemotherapy induced peripheral neuropathy is a significant dose-limiting
toxicity that adversely affects the lives of cancer patients. This symptom has been underreported, minimized by oncology practitioners, and inaccurately described as a minor
problem. There are many gaps in the knowledge of standardized nursing assessment,
interventions, and patient education in the literature. Oncology nurses need to be aware of
the current state of the literature, and become knowledgeable of the distressing influence
CIPN has on daily living. Nurses can advocate for patients by understanding the
pathophysiology of CIPN, identifying risk factors, educating patients on early symptoms,
collaborating with the healthcare team, and by anticipating the care the patient will
require. This knowledge and empowerment may minimize, or alleviate the burden of
CIPN. Nurses have great opportunity to evaluate their own gaps in knowledge of CIPN
for the preservation of safety and improved quality of life of the oncology patient.
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Chapter III: Methods
This chapter outlines the research methods. Specifically the sample and setting,
instrument, validity and reliability, consent process, and procedure for data collection and
data synthesis are presented here. This project was a prospective, cross-sectional,
descriptive study exploring oncology nurses’ knowledge, practice behaviors, and
confidence in assessing CIPN.
Sample
This study was conducted at four Florida Oncology Nursing Society Chapter
meetings located on the west and east coast and central Florida. The sample consisted of
oncology nurses who are Oncology Nursing Society members and are chapter attendees.
Study inclusion criteria supported participation from registered nurses who are currently
providing or have in the past provided direct care to medical oncology-hematology
patients and who can read, write, and speak English. Nurses whose oncology career has
been outside of a medical oncology setting (i.e. critical care, surgical- oncology) were
excluded.
Instrumentation
Chemotherapy-Induced Peripheral Neuropathy: Assessment of Oncology Nurses’
Knowledge and Practice-Revised.
The Chemotherapy-Induced Peripheral Neuropathy (CIPN): Assessment of
Oncology Nurses’ Knowledge and Practice-Revised instrument assesses the knowledge,
practice behaviors and confidence oncology nurses have specific to CIPN (Appendix A)
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(Binner, 2010). This instrument was selected because it is the only available tool
evaluating nurses’ knowledge, practice behaviors, and confidence pertaining to CIPN.
This questionnaire contains sixteen knowledge items, sixteen practice items, five
confidence items, and nine-item demographic survey questions specific to skills,
instruction, and perceptions. The CIPN knowledge questions score can range from 0-16
based on number of correct answers. Unanswered questions are counted as incorrect.
Practice domain questions are each rated to indicate frequency of practice behaviors on a
scale of 0-3 (Never, occasionally, frequently, and always). The self-rated confidence
questions are rated to indicate level of confidence in performing neurological physical
assessment skills on a scale of 0-3 (Not at all confident, somewhat confident, confident,
and very confident). These are not summed however, are reported as percentages (Binner,
2010).
Validity and Reliability
To assess Content validity the Assessment of Oncology Nurses’ Knowledge and
Practice-Revised instrument was evaluated by a panel of experts including two medical
oncologist and three PhD prepared nurses who have published on CIPN. The instrument
content-validity index was 0.95. Internal consistency reliability was evaluated using
Cronbach’s alpha. The alpha coefficient for the entire instrument was 0.84 (Binner,
2010).
Procedures
First, written permission to use the selected instrument was obtained from the
author of the Chemotherapy-Induced Peripheral Neuropathy: Assessment of Oncology
Nurses’ Knowledge and Practice-Revised instrument (Appendix B).Written permission

20

was then obtained from the Presidents of four Oncology Nursing Society (ONS) Chapters
in Florida for the purpose of collecting data at their chapter meetings (Appendices C, D,
E, & F). The Institutional Review Board (IRB) at the University of South Florida (USF)
granted exempt status, so this study would be exempt from the process of signed consent
(Appendix G). After study approval by the USF IRB, the CIPN: Assessment of Oncology
Nurses’ Knowledge and Practice-Revised questionnaire was administered to a group of
oncology nurses at the beginning of the Oncology Nursing Society (ONS) Chapter
meeting held on the west coast, followed by an east coast chapter meeting, then a chapter
meeting held in central Florida, with data collection ending at a meeting held on the west
coast of Florida. The purpose of the study, study requirements, confidentiality, and
voluntary participation were explained. Nurses were informed that by completing the
questionnaire informed consent would be implied. All questions were answered to
participants’ satisfaction. All data was kept anonymous and confidential. An assumption
is that all oncology nurses have access to the literature regarding CIPN.
Data Analysis
Descriptive statistics were utilized to analyze the demographic data including
frequencies and percentages, means, and standard deviations. Relationships between
variables were assessed using the Pearson correlation coefficient. Data was analyzed
using SPSS software version 16.0 to answer the research questions: Means and Standard
deviations were utilized to answer research question one. Research questions two and
three were addressed using frequencies and percentages. Pearson correlations were
utilized to answer research question four.
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Chapter IV: Results, Discussion, and Conclusions
This chapter outlines the findings of this cross-sectional, descriptive study. The
results, discussion, conclusions, and recommendations for future research are presented.
Results
Demographic Data
The sample consisted of 70 oncology nurses, which included 69 females with
demographic data missing on one participate. The age range of the participants was from
26 to 68 years. The overall nursing experience, ranged from 1 to 47 years with experience
specific to oncology nursing, ranging from 6 months to 32 years (Table 2).
Table 2
Mean and Standard Deviation of Demographic Variables for Participants
Demographic Variable
Mean
SD
Age

50.2

9.5

Years in Nursing

24.7

12.2

Years in Oncology
13.5
Note. Demographics (n=70, missing data on 1 participant).

7.4

The participants varied in educational levels with both nursing education and
highest education degree achieved examined (Table 3). In the nursing education category
59 (74.3%) of the 70 participants had undergraduate degrees (Diploma, Associate of
Science, or Bachelors of Science) while 10 (14.3%) had Masters of Science (9) or
Doctoral (1) degrees. The highest education level achieved category was higher in
Masters of Science (2.8%) and Doctoral degrees (1.5%) compared to nursing education
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level category. Most were currently employed as registered nurses (85.7%) with a small
subgroup (8.6%) employed as nurse practitioners. Among the participating oncology
nurses, 65.7% held oncology certification.
Table 3
Frequency and Percent of Education and Clinical Characteristics
Demographic Variable
Response a
Frequency

Percent

Generic Nursing Education Level

Diploma
Associate
Bachelors
Masters
Doctorate

9
21
29
9
1

12.9
30.0
41.4
12.9
1.4

Highest Attained Education Level

Diploma
Associate
Bachelors
Masters
Doctorate

7
21
28
11
2

10.0
30.0
40.0
15.7
2.9

Current Position

RN
CNS
NP
Other

60
1
6
2

85.7
1.4
8.6
2.9

Oncology Nursing Certification

No
Yes

23
46

32.9
65.7

Certification Type

None
23
35.7
OCN
40
57.1
AOCNP
3
4.3
OCCNS
0
0
Other
3
1.4
Note. (n=69). aRN=Registered Nurse. CNS=Clinical Nurse Specialist. NP=Nurse
Practitioner. OCN=Oncology Certified Nurse. AOCNP=Advanced Oncology Certified
Nurse. OCCNS=Oncology Certified Clinical Nurse Specialist.
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CIPN Knowledge
The participant’s level of knowledge in non-pharmacologic management,
pharmacologic agents, neuropathy terminology, assessment principals, and
symptomatology specific to CIPN was assessed. The mean CIPN knowledge score was
13.0 (SD=1.9) (81%) of 16.0 (Table 4).
Table 4
Mean and Standard Deviation of Knowledge Scores
Variable
Minimum
Maximum
CIPN Knowledge

8.0

16.0

Mean

SD

13.0

1.9

Practice Behaviors
Participants practice behaviors were assessed by self-reported evaluation of
screening patterns, assessment skills, documentation, and patient teaching related to
CIPN (Table 5). Screening for peripheral neuropathy prior to initiating the first dose of
neurotoxic chemotherapy was always or frequently performed by 35, (50.0%) of
participating oncology nurses. Evaluating patient’s fine motor skills was always or
frequently done by 48 (68.6%) oncology nurses surveyed. Documentation of CIPN
assessment findings was always or frequently documented by 45 (64.3%) nurses caring
for this population of patients. Only 12 (17.2%) oncology nurses reported always or
frequently assessing deep tendon reflexes. Muscle strength was always or frequently
measured by only 25 (35.7%) oncology nurses. An assessment of other risk factors
associated with peripheral neuropathy was always or frequently assessed among 39
(55.7%) oncology nurses. Fine motor function such as evaluating gait, was always or
frequently inspected by 37 (52.9%) oncology nurses surveyed. Of those surveyed, 41
(58.6%) always, frequently incorporate CIPN assessment prior to each infusion of a
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neurotoxic agent. Eliciting symptoms of CIPN from patients. was always or frequently
done by 47 (65.7%) oncology nurses Teaching patient strategies for adapting to CIPN
functional impairment was always or frequently taught by 40 (57.1%) of oncology
nurses. Educating patients regarding safety precautions used to avoid injury, among those
suffering from CIPN was always or frequently instilled by 52 (74.3%) oncology nurses
who care for those affected by CIPN.
Level of Confidence
The level of self-confidence among the participants (n=70) in performing a
neurological physical examination by assessing deep tendon reflexes, tuning fork
vibration sensation, sharp vs. dull sensation, Romberg test, and manual muscle strength
testing was evaluated (Table 6). The majority 50 (71.5%) of nurses reported a lack of
confidence in assessing deep tendon reflexes, a lack of confidence in using a tuning fork
to assess vibration sensation 51 (72.8%) and a lack of confidence in performing Romberg
testing 51 (72.8%). Most, 62.8% reported being confident in performing the sharp vs. dull
sensation assessment skill, and a reported 37 (52.9%) oncology nurses reported
confidence in assessing manual muscle strength.
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Table 5
Frequency and Percent of Practice Behaviors
Self-Reported Practice Behavior

Response

Frequency

Percent

Never
Occasionally
Frequently
Always
Never
Occasionally
Frequently
Always

8
27
23
12
10
12
37
11

11.4
38.6
32.9
17.1
14.3
17.1
52.9
15.7

Document CIPN assessment data

Never
Occasionally
Frequently
Always

7
18
30
15

10.0
25.7
42.9
21.4

Assess deep tendon reflexes

Never
Occasionally
Frequently
Always

38
20
9
3

54.3
28.6
12.9
4.3

Assess muscle strength

Never
Occasionally
Frequently
Always

17
28
20
5

24.3
40.0
28.6
7.1

Assess for other risk factors associated with peripheral neuropathy

Never
Occasionally
Frequently
Always

5
26
25
14

7.1
37.1
35.7
20.0

Assess motor function skills (e.g., gait)

Never
Occasionally
Frequently
Always

7
26
27
10

10.0
37.1
38.6
14.3

Perform CIPN assessment prior to each neurotoxic chemotherapy infusion Never
Occasionally
Frequently
Always

13
16
25
16

18.6
22.9
35.7
22.9

Elicit symptoms related to CIPN

Never
Occasionally
Frequently
Always

6
18
36
10

8.6
25.7
51.4
14.3

Teach patient strategies for adapting to CIPN functional impairment

Never
Occasionally
Frequently
Always

10
20
35
5

14.3
28.6
50.0
7.1

Teach safety precautions used to prevent injuries associated with CIPN
(e.g., falls)

Never
Occasionally
Frequently
Always

8
10
35
17

11.4
14.3
50.0
24.3

Screen for baseline peripheral neuropathy

Assess fine motor skills
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Table 6
Frequency and Percent of Confidence in Performing Neurological Physical
Assessment Skills
Assessment Skill
Confidence Level
Frequency
Percent
Response
Deep tendon reflexes
Not at all Confident
23
32.9
Somewhat Confident
27
38.6
Confident
17
24.3
Very Confident
3
4.3
Tuning fork vibration
sensation

Not at all Confident
Somewhat Confident
Confident
Very Confident

29
22
15
4

41.4
31.4
21.4
5.7

Sharp vs. dull sensation

Not at all Confident
Somewhat Confident
Confident
Very Confident

9
17
32
12

12.9
24.3
45.7
17.1

Romberg test

Not at all Confident
Somewhat Confident
Confident
Very Confident

36
15
13
6

51.4
21.4
18.6
8.6

Manual muscle strength
testing

Not at all Confident
Somewhat Confident
Confident
Very Confident

11
22
24
13

15.7
31.4
34.3
18.6

Previous Education and Experience
The participants’ previous education and experience obtained from demographic
data was correlated with their knowledge pertaining to CIPN (n=69). Utilizing Pearson
Correlation there was no significant relationship between generic nursing education level
attained and knowledge of CIPN (r=.233, p=.054). There was however, a significant
relationship between the highest education level achieved and CIPN knowledge
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(r=.252, p=.037). Neither the number of years of experience in nursing nor the number of
years of experience specific to oncology nursing were correlated with knowledge of
CIPN.
Discussion
This study was initiated in recognition of the profound, negative effect CIPN has
on the daily living of patients with varied cancer diagnoses and the lack of a standard
approach among oncology nurses in addressing the care of patients who receive
neurotoxic agents. This study may validate the existence of gaps in oncology nursing
knowledge, practice behaviors and confidence pertaining to CIPN. These deficits, unless
corrected, negatively influence patient outcomes, physical function, and enjoyment of life
in those who are diagnosed with CIPN.
Demographic Data
Oncology registered nurses from ONS Chapter meetings across Florida
participated in this prospective, cross-sectional descriptive study exploring oncology
nurses’ knowledge, practice behaviors, and confidence in assessing CIPN. The
participants consisted of registered nurses, nurse practitioners, a clinical nurse specialist,
and nursing educators with the majority having undergraduate degrees. The sample was
reflective of diverse oncology practice settings including inpatient hospital nurses,
outpatient clinic nurses, and outpatient infusion nurses. The years of nursing experience
and the years devoted specifically to oncology demonstrates participants are very
experienced clinically and were very experienced in the care of the oncology patient.
Most participants held oncology certification. A limitation of this prospective study is the
relatively small sample size considering the number of eligible ONS members. Data were
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not collected from a single site, but from several ONS chapters in different geographical
regions throughout Florida. This makes the results from this study more generalizable.
However, further study is needed in other states. Another study limitation was the
potential for social desirability bias, whereby the participants may reply in a manner that
is viewed as most favorable or correct. Further, nurses who choose to attend ONS
meetings may be systematically different from other nurses who do not attend.
CIPN Knowledge
The mean CIPN knowledge score indicated adequate knowledge in the areas of
non-pharmacologic management, pharmacologic agents, neuropathy terminology,
assessment principals, and symptomatology specific to CIPN. Although the knowledge
score is adequate, the scores range from 50%-100% (n=70) (Table 4). The initial crosssectional exploratory study piloting this questionnaire obtained similar results with a
mean knowledge score 12.6 (79%) (1.7) indicating adequate nursing knowledge (Binner,
2010).
With the wide range in overall knowledge scores, this indicates there is a need for
on-going education regarding the non-pharmacologic management, pharmacologic
agents, neuropathy terminology, assessment principals, and symptomatology specific to
CIPN among new oncology nurses and experienced oncology nurses alike. Education
through continuing education programs, oncology nursing specific educational forums,
college courses, and pharmaceutical industry initiated educational endeavors are
necessary in providing oncology nurses’ with the knowledge necessary to care to patients
receiving neurotoxic chemotherapeutic agents.
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Practice Behaviors
The practice behaviors subscales address screening, assessment skills,
documentation, and teaching specific to CIPN (Table 5). Screening incorporates an
assessment of baseline peripheral neuropathy symptoms prior to initiating the first dose
of chemotherapy, assessment of other risk factors associated with peripheral neuropathy,
and nursing assessment prior to each infusion of a neurotoxic agent. While the majority
of the participants perform screening assessments prior to the first dose of chemotherapy,
a significant number do not (Table 5). This data is consistent with the data reported by
Binner (2010).
Some conditions and co-morbidities can make patients more prone to developing
the complication of CIPN. Cancer, autoimmune disorders, nutritional deficiencies, kidney
disorders, vascular and metabolic disorders, infectious diseases, and hereditary disease
can cause baseline peripheral neuropathy (Wickham, 2006). It is essential in oncology
nursing practice to assess for risk factors to determine who may need closer monitoring
for CIPN during treatment. Baseline neurological assessment and assessment prior to
each dose of neurotoxic chemotherapy allows the nurse and healthcare team to recognize
changes in peripheral neuropathy once therapy has begun.
Assessment of CIPN incorporates fine motor skills, assessment of deep tendon
reflexes, muscle strength, motor function skills, and eliciting symptoms related to CIPN.
An assessment of motor, sensory, and autonomic function must be performed before,
during, and after the completion of chemotherapy. An assessment specific to CIPN
should include history, deep tendon reflexes, muscle strength, motor function, and an
assessment of autonomic function (Armstrong, et al., 2005). Evaluating fine motor skills
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by observing patients’ ability to grasp small objects or manipulate buttons on clothing
can identify functional problems associated with CIPN (Armstrong, et al., 2005). Deep
tendon reflex testing of the upper and lower extremities can provide information on the
integrity of the peripheral nervous system with decreased reflexes indicate peripheral
nervous system dysfunction. Muscle strength testing, noting weakness, and symmetry can
provide information on the presence of motor fiber involvement by CIPN (Bickley, &
Szilagyi, 2009). Assessing motor function by observing gait for unsteadiness, shuffling,
wide base steps, or pain with ambulation may indicate CIPN (Armstrong, et al., 2005).
Asking patients about the presence of CIPN may be as important as performing
neurological testing (Rambaud, et al., 2001).
The majority of oncology nurses reported incorporating assessment of fine motor
and, gross motor function skills, and eliciting symptoms of CIPN routinely into practice
while deep tendon reflex and muscle strength assessments are integrated with much less
frequency. The ability to assess fine motor skills, elicit symptoms of CIPN, and motor
function assessment may occur with greater frequency because of limited time required to
assess for CIPN utilizing these assessment measures. This may also suggest greater
confidence in interpreting the outcome of these functions with accuracy. Despite the
increased frequency compared to other assessment skills, there remains a significant
portion of nurses who do not incorporate these simple, although important, neurological
assessments in their daily care of patients at risk for CIPN. Another consideration is
oncology nurses may not be asking the proper questions to elicit symptoms related to
CIPN. Muscle strength assessment and deep tendon reflex evaluation occurs with less
frequency. This may indicate that these functions require a higher level of physical
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assessment skill and may be perceived as the responsibility of the physician or nurse
practitioner. These assessment skills also require time to perform, suggesting oncology
nurses may not be working in an environment conducive to performing these skills on a
routine basis due to time constraints.
Binner (2010) found assessment of deep tendon reflexes, assessment of muscle
strength, and assessment of motor function skills were incorporated into oncology
nursing practice with much less frequency than assessment of fine motor skills and
eliciting of CIPN symptoms. This difference between the two studies in frequency of
assessing motor function skills may be related to a larger sample size, the diversity in
clinical settings, and the influence of advance practice nurses included in the sample of
the present study.
Oncology nurses were asked to evaluate the frequency of documenting CIPN
assessment data with the majority reportedly documenting assessment findings. A
limitation of this study is elements of documentation pertaining to CIPN assessment and
practice behaviors in oncology nursing practice are not included in this study. Further
study is needed. The data supports that oncology nurses do not routinely incorporate
screening, physical neurological assessment, or teaching related to adaptation and safety
into practice. This suggests critical elements specific to CIPN are missing from the
medical record. This creates a lack of continuity in patient care with an inability to follow
improvement or progression of symptoms between treatment cycles. Binner (2010)
reported consistent data.
Teaching was assessed by evaluating the frequency of occurrence in educating
patients on strategies for adapting to the functional impairment induced by CIPN and the
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frequency of educating patients on safety precautions used to prevent injuries associated
with CIPN. The majority of oncology nurses self-reported teaching patient strategies for
adapting to CIPN functional impairment and educating patients regarding safety
precautions used to avoid injury associated with CIPN. Binner (2010) obtained differing
outcomes, the majority of oncology nurses reported never or occasionally teaching
strategies for adaptation, while the majority always or frequently taught safety
precautions.
A significant number of oncology patients are not given strategies by their
oncology nurse to adapt to the functional impairment. This may suggest oncology nurses
feel helpless when functional deficits become evident. Safety precautions were not
consistently addressed by approximately one-forth of the participants. This may reflect
oncology nurses are unaware of how patients are forced to live or function at home with
CIPN. There may also be a knowledge deficit on behalf of oncology nurses regarding the
functional effects of CIPN by affected body location.
Tofthagen (2010) suggests a multidisciplinary approach to CIPN. Open dialogue
regarding the patients’ symptoms and performance status with the physician can ensure
proper decisions are made regarding continued treatment utilizing the causative agent.
Occupational therapy and physical therapy can have a vital role in assisting with
maintaining functional capacity and evaluating safety needs. Identifying potential safety
hazards in the home may help patients avoid injuries. Oncology nurses can provide
anticipatory guidance in preparing patients for possible changes in physical, social, or
emotional function.
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Level of Confidence
The level of self-confidence among the participants in performing a neurological
physical examination by assessing deep tendon reflexes, tuning fork vibration sensation,
sharp vs. dull sensation, Romberg test, and manual muscle strength testing was assessed
(Table 6). The majority of participants reported greater confidence in performing sharp
vs. dull sensation and manual muscle strength testing while having less confidence in
assessing deep tendon reflexes, tuning fork vibration sensation testing, and Romberg
testing. Sharp vs. dull sensation testing and manual muscle strength testing require only
simple assessment tools for performing these functions. The lack of confidence in
assessing deep tendon reflexes, tuning fork vibration and Romberg testing may indicate
these skills requires a higher level of assessment knowledge in performing and there may
be a knowledge deficit in interpreting the findings. Perhaps oncology nurses were never
educated in performing these skills. These neurological assessment skills may be
perceived as the responsibility of the physician or nurse practitioner. Binner (2010) did
not report the level of confidence and perhaps this is an area for future exploration.
Previous Education and Experience
A significant, but weak relationship was identified between the highest
educational level attained and CIPN knowledge, while no significant relationship was
identified between nursing experience and knowledge of CIPN. The participants varied in
their highest attained educational level; while most had Bachelor of Science degrees there
were more Masters of Science and Doctoral degrees compared to basic nursing
education. This relationship finding may represent a positive difference in higher
education with specialized knowledge and oncology nurses’ ability to translate what is
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learned into the clinical setting. Binner did not report on this relationship and may be an
area of future exploration.
Conclusions
This is one of a few studies to document oncology nurses’ practice behaviors, and
confidence, in addition to knowledge, and the relationship between education,
experience, and knowledge of oncology nurses pertaining to CIPN. This study documents
the current state of oncology nurses’ practice. The results support the need for enhancing
the neurological assessment skills of oncology nurses. An efficient approach to CIPN
assessment is needed to address the time constraints of the outpatient setting and the
skillfulness required by oncology nurses in assessing for CIPN. The roles and
responsibilities of assessing for CIPN should be delineated among oncology practices to
overcome the ambiguity that currently exist among oncology nurses until evidence based
CIPN assessment practice guidelines are developed. This study lays the foundation for
future research and should serve as a stimulus for future studies.
Recommendations for Future Research
Oncology nurses desiring to capture a true reflection of assessment skills, practice
behaviors, and patient outcomes related to CIPN have tremendous opportunity to
contribute to the literature. A questionnaire examining the roles, responsibilities,
perceptions, and barriers for healthcare providers in assessing and managing CIPN would
provide further insight. Another area of exploration is a retrospective review of the
medical record examining healthcare provider’s documentations of patients receiving
neurotoxic agents. This would provide information into the assessment, and management
of CIPN on behalf of nurses and physicians. Elements of patient descriptions of CIPN
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could also be captured. This form of research would enable data collection and outcome
measurement in a setting where no attempt is made to affect the outcome. Additional
studies are needed to examine how patients live each day with CIPN, bringing attention
and urgency to improving on our current practice and to the development of prevention
and treatment strategies. Another area to explore where limited knowledge exists is the
relationship between CIPN, interpersonal relationships, and sexual function. The piloting
of a comprehensive CIPN patient assessment tool that is conducive to use in the current
clinical environment is needed. Intervention studies are also needed to provide guidance
on the prevention, and management of CIPN, and for the preservation of patient safety.
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Appendix A
CIPN: Assessment of Oncology Nurses’ Knowledge and Practice-Revised

Multiple choices: Please check the best response.
1. Nonpharmacologic strategies to consider in the management of symptoms associated with
CIPN include all of the following except:
Ο Use of assistive devices (e.g., cane, orthotic brace, splint
Ο Use of heating pad
Ο Transcutaneous nerve stimulations (TENS)
Ο Acupuncture
2. Chemotherapy agents commonly associated with CIPN include:
Ο Paclitaxel, Vincristine, and Doxorubicin
Ο Paclitaxel, Cisplatin, and Gemcitabine
Ο Cisplatin, Gemcitabine, and Doxorubicin
Ο Paclitaxel, Cisplatin, and Vincristine
3. An unpleasant, abnormal sensation is called:
Ο Dystonia
Ο Ataxia
Ο Dysesthesia
Ο Hyperreflexia
4. All of the following are part of the assessment of patients suspected of having CIPN except:
Ο A test for impaired sense of balance
Ο A test for deep tendon reflexes
Ο Auscultation of lung sounds
Ο Auscultation of bowel sounds
5. A critical element in the clinical assessment of patients with CIPN is to:
Ο Monitor vital signs during neurotoxic chemotherapy infusions
Ο Determine the level of functional impairment involving ADLs
Ο Evaluate patient’s orientation to time, place, and person
Ο None of the above
6. The essential first step in assessing CIPN is:
Ο Sensory motor evaluation
Ο Motor system evaluation
Ο Patient interview
Ο Autonomic system physical assessment
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True/False: Check the correct response
7. Orthostatic hypotension may indicate autonomic CIPN.
Ο True
Ο False
8. Chemotherapeutic agents causing CIPN may affect position and vibration sense.
Ο True
Ο False
9. Impaired proprioception may be a symptom of CIPN.
Ο True
Ο False
10. The peripheral nervous system includes autonomic nerves.
Ο True
Ο False
11. Sensory symptoms of CIPN typically progress in a proximal to distal pattern.
Ο True
Ο False
12. The stocking-glove distribution of sensory symptoms of CIPN refers to the paresthesias in the
hands and feet.
Ο True
Ο False
13. Toxicity scales used to grade CIPN are very precise.
Ο True
Ο False
14. Patients readily report symptoms of peripheral neuropathy.
Ο True
Ο False
15. Oncology patients with diabetes or alcoholism are at greater risk for developing CIPN.
Ο True
Ο False
16. Assessment of neuropathic pain requires a separate and unique approach compared assessment
of nociceptive (tissue) pain.
Ο True
Ο False
How often do you do each of the following in your nursing practice? Check one for each
question.
17. How often do you screen patients for baseline presence of peripheral neuropathy prior to
initiating the first dose of chemotherapy?
Ο Never
Ο Occasionally
Ο Frequently
Ο Always
18. How often do you assess patient’s ability to perform fine motor skills (e.g., button clothes, use
of zippers) if they are receiving neurotoxic chemotherapeutic agents?
Ο Never
Ο Occasionally
Ο Frequently
Ο Always
19. How often do you document CIPN assessment data if the patient is receiving chemotherapy
associated with CIPN?
Ο Never
Ο Occasionally
Ο Frequently
Ο Always
20. How often do you assess deep tendon reflexes on patients receiving neurotoxic chemotherapy?
Ο Never
Ο Occasionally
Ο Frequently
Ο Always
21. How often do you assess muscle strength in patients receiving neurotoxic chemotherapy?
Ο Never
Ο Occasionally
Ο Frequently
Ο Always
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22. How often do you assess patients for the presence of other risk factors associated with
peripheral neuropathy?
Ο Never
Ο Occasionally
Ο Frequently
Ο Always
23. How often do you perform objective motor function assessment skills (e.g., muscle strength,
gait assessment)?
Ο Never
Ο Occasionally
Ο Frequently
Ο Always
24. How often do you perform nursing assessment of CIPN prior to each infusion of neurotoxic
chemotherapy?
Ο Never
Ο Occasionally
Ο Frequently
Ο Always
25. How often do you attempt to elicit patient symptoms related to chemotherapy-induced
peripheral neuropathy?
Ο Never
Ο Occasionally
Ο Frequently
Ο Always
26. How often do you teach patients strategies for adapting to functional impairments secondary to
CIPN?
Ο Never
Ο Occasionally
Ο Frequently
Ο Always
27. How often do you educate patients about safety precautions used to avoid injuries associated
with CIPN (e.g., thermal injury, falls)?
Ο Never
Ο Occasionally
Ο Frequently
Ο Always
28. Check your level of confidence in performing each of the following physical assessment skills:
a. Deep tendon reflexes
Ο Not at all Confident

Ο Somewhat Confident

Ο Confident

Ο Very Confident

b. Tuning fork vibration sensation
Ο Not at all Confident Ο Somewhat Confident

Ο Confident

Ο Very Confident

c. Sharp vs. dull sensation
Ο Not at all Confident Ο Somewhat Confident

Ο Confident

Ο Very Confident

d. Romberg test
Ο Not at all Confident

Ο Somewhat Confident

Ο Confident

Ο Very Confident

e. Manual muscle strength testing
Ο Not at all Confident Ο Somewhat Confident

Ο Confident

Ο Very Confident

29. Is CIPN a significant problem for your patients receiving neurotoxic chemotherapy agents?
Ο Yes
Ο No
30. Have you ever had instruction in assessment of CIPN?
Ο Yes
Ο No
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31. Have you had instruction in physical assessment of CIPN in performing the following
technique?
a. Cranial nerves assessment Ο Yes Ο No
b. Deep tendon reflexes
Ο Yes Ο No
c. Muscle strength
Ο Yes Ο No
d. Orthostatic blood pressure Ο Yes Ο No
e. Romberg test
Ο Yes Ο No
f. Temperature sensation
Ο Yes Ο No
g. Dull/sharp sensation
Ο Yes Ο No
h. Vibration sensation
Ο Yes Ο No
32. Have you had instruction in:
a. Pharmacology management of CIPN?
b. Non-pharmacologic management of CIPN?

Ο Yes
Ο Yes

Ο No
Ο No

33. Do you believe assessment of CIPN is essential in your role as an oncology nurse?
Ο Yes
Ο No
34. How would you rate the adequacy of your skill in assessing CIPN? (Check one)
Ο Poor
Ο Fair
Ο Good
Ο Excellent
35. Are patients routinely assessed for CIPN in your setting?
Ο Yes
Ο No
36. If CIPN assessment is not routinely performed state reason. __________________________
Demographics
37. Gender

ΟM

ΟF

38. Age ___________
39. Years in Nursing ________
40. Years in oncology nursing __________
41. Generic Nursing Education (check highest level attained)
Ο Diploma
Ο Associate
Ο Bachelors
Ο Masters
Ο Doctorate
42. Education (check highest level attained)
Ο Diploma
Ο Associate
Ο Bachelors
Ο Masters
Ο Doctorate
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43. In your current position, are you a: (check one)
Ο RN
Ο CNS
Ο NP
Ο Other (please indicate) _____________
44. Do you have Oncology Nursing Certification?
Ο Yes
Ο No
45. If yes, please indicate which certification(s) you hold:
Ο OCN
Ο AOCNP
Ο OCCNS Ο Other (please indicate) _____________
Additional Comments:
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________

Thank You For Your Participation

Chemotherapy-Induced Peripheral Neuropathy (CIPN):
Assessment of Oncology Nurses’ Knowledge and Practice-Revised
© 2010 by Madelaine Binner--- Permission required for use and copying
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